
    
      A multicentre, two-staged with interim analysis, parallel, randomised, double blind,
      placebo-controlled, dose-ranging study of the safety, tolerability, and effects on plasma
      high-density lipoprotein cholesterol (HDLc) of 12 weeks treatment with 2.5mg, 5mg and 10mg
      daily doses of GW501516 in subjects with low HDLc
    
  